NASDAQ:ZIVO ZIVO Bioscience (ZIVO) Stock Price, News & Analysis $4.00 0.00 (0.00%) As of 07/21/2026 01:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock About ZIVO Bioscience Stock (NASDAQ:ZIVO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ZIVO Bioscience alerts:Sign Up Key Stats Today's Range$4.00▼$4.3850-Day Range$3.05▼$5.2552-Week Range$1.11▼$19.65Volume413 shsAverage Volume3,211 shsMarket Capitalization$16.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ZIVO Bioscience is a clinical-stage biotechnology company focused on developing precision live biotherapeutics to prevent and treat gastrointestinal infections in both animal and human health markets. The company applies synthetic biology, microbiology and fermentation technologies to engineer proprietary bacterial strains that produce targeted lactic acid and antimicrobial compounds. Its pipeline includes ZB-01, an orally administered therapy for recurrent Clostridioides difficile infections in humans, and ZB-02, a feed-additive candidate aimed at reducing Salmonella colonization in poultry. Founded in 2016 and headquartered in Carlsbad, California, ZIVO Bioscience leverages exclusive licensing agreements with academic institutions to advance its lead programs through preclinical and early clinical development. The company’s animal health platform is designed to offer an antibiotic‐free approach to controlling foodborne pathogens, while its human health efforts target high-unmet-need gastrointestinal diseases where current therapies fall short or carry significant safety risks. ZIVO’s proprietary fermentation processes are scalable and designed to meet regulatory standards for both veterinary and human therapeutics. The company collaborates with contract development and manufacturing organizations (CDMOs) to produce its live bacterial formulations under Good Manufacturing Practices (GMP). These partnerships aim to accelerate the transition of ZIVO’s pipeline assets from research to first-in-human trials and commercial supply. Under the leadership of CEO Jon Bany, ZIVO Bioscience continues to build a multidisciplinary team of experts in microbiology, immunology and process development. The company’s strategic focus on dual animal and human health applications reflects a growing industry emphasis on microbiome-based solutions that improve public health outcomes while addressing regulatory pressures to reduce antibiotic use in agriculture.AI Generated. May Contain Errors. Read More Receive ZIVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ZIVO Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZIVO Stock News HeadlinesZivo Bioscience, Inc. Announces Transition to OTCID MarketplaceMay 12, 2026 | businesswire.comZivo Bioscience Inc. WtApril 11, 2026 | barrons.comBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.July 22 at 1:00 AM | Awesomely (Ad)ZIVO Bioscience Provides Special Letter to ShareholdersMarch 27, 2026 | businesswire.comMaxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)December 15, 2025 | theglobeandmail.comZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic BusinessesSeptember 10, 2025 | businesswire.comZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in PoultryJune 20, 2025 | businesswire.comUniversity of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryMay 7, 2025 | finance.yahoo.comSee More Headlines ZIVO Stock Analysis - Frequently Asked Questions How have ZIVO shares performed this year? ZIVO Bioscience's stock was trading at $8.70 at the beginning of 2026. Since then, ZIVO shares have decreased by 54.0% and is now trading at $4.00. How were ZIVO Bioscience's earnings last quarter? ZIVO Bioscience, Inc. (NASDAQ:ZIVO) posted its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.06) earnings per share for the quarter. The biotechnology company had revenue of $0.02 million for the quarter. When did ZIVO Bioscience's stock split? ZIVO Bioscience shares reverse split on Friday, October 27th 2023.The 1-6 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. How do I buy shares of ZIVO Bioscience? Shares of ZIVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ZIVO Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that ZIVO Bioscience investors own include Canopy Growth (CGC), Meta Platforms (META), OPKO Health (OPK), Johnson & Johnson (JNJ), ACADIA Pharmaceuticals (ACAD), Aravive (ARAV) and Alibaba Group (BABA). Company Calendar Last Earnings5/11/2020Today7/22/2026Next Earnings (Estimated)9/02/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZIVO Previous SymbolOTCMKTS:HEPI CIK1101026 Webwww.zivobioscience.com Phone(248) 452-9866FaxN/AEmployees10Year Founded1999Profitability EPS (Trailing Twelve Months)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.78 million Net MarginsN/A Pretax Margin-17,113.75% Return on EquityN/A Return on Assets-2,240.92% Debt Debt-to-Equity RatioN/A Current Ratio0.17 Quick Ratio0.17 Sales & Book Value Annual Sales$15.85 thousand Price / Sales1,047.82 Cash FlowN/A Price / Cash FlowN/A Book Value($0.81) per share Price / Book-4.94Miscellaneous Outstanding Shares4,152,000Free Float2,911,000Market Cap$16.61 million OptionableNot Optionable Beta0.10 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ZIVO) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersAmerica’s answer to universal basic incomeRobert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredTSM just handed Trump's secretive AI project $100 billionTaiwan Semiconductor just committed another $100 billion to U.S. chip manufacturing - on top of $165 billion a...InvestorPlace | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredElon is about to dominate the biggest arms race in tech historyMicrosoft, Amazon, Alphabet, and Meta have collectively poured nearly $700 billion into AI infrastructure in 2...The Oxford Club | SponsoredThis could help save your retirementMurray Stahl is a Wall Street money manager who put more than half of his $9 billion firm into a single stock ...Stansberry Research | SponsoredIt all happens tonight.Tonight, trader Sean Allison is hosting a live session to walk through his Zero-Dollar Trade Advantage strateg...Trade Thirsty | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZIVO Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZIVO Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
